We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nektar Therapeutics reported that Pfizer Inc announced that Pfizer will introduce Exubera (insulin human (rDNA origin)) Inhalation Powder in the U.S. by commencing a comprehensive physician and patient education and training program for this landmark innovation in diabetes treatment on July 24, 2006, that will be rolled out in phases.
Infinity Pharmaceuticals Inc. announced that Amgen Inc. has extended its non-exclusive access to Infinity's collection of diverse, natural product-like compounds for drug discovery.
OVATION Pharmaceuticals announced its launch of the first new pharmaceutical product in 20 years to treat a potentially life-threatening congenital heart defect in premature infants.
The FDA's Center for Biologics Evaluation and Research (CBER) has issued a guidance on how manufacturers of biologic products should submit their lot release protocols in electronic format to CBER's Product Release Branch.
Sen. Chuck Grassley (R-Iowa) is accusing the agency of actively working with Merck to discredit a Vioxx whistleblower and is asking the HHS Office of Inspector General to investigate this claim.
The immune response against the virus that causes cervical cancer is stronger and sustained following vaccination with GlaxoSmithKline's (GSK) candidate HPV vaccine formulated with the innovative AS04 adjuvant compared to using the same vaccine formulated with a conventional aluminium salt adjuvant.